BlackRock’s Gilead Sciences GILD Stock Holding History

BlackRock’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-7,000	Closed	-$496K	–	3179
2014 Q1	$496K	Buy	+7,000	New	+$549K	﹤0.01%	1334

Other funds holding GILD

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock's GILD Position: Q1 2026 in Review

BlackRock reduced its Gilead Sciences (GILD) stake by 3.4% in Q1 2026, selling an estimated $586M and leaving 119,010,973 shares worth $16.6B. The position accounts for 0.29% of the portfolio, ranked #54.

BlackRock first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

BlackRock held 119,010,973 shares of Gilead Sciences worth $16.6B as of Q1 2026.
BlackRock sold 4,184,605 Gilead Sciences shares in Q1 2026, an estimated $586M.
Gilead Sciences made up 0.29% of BlackRock's portfolio in Q1 2026, its #54 holding.
BlackRock first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.